Corsair Pharma
PrivateLast Round
Series B
Sep 20, 2023
Total Funding Raised
$23M
Company Overview
Corsair Pharma operates in Healthcare & Life Sciences and is based in Sunnyvale, California. Its latest recorded funding round was a Series B round in September 2023.
Corsair Pharma is a biotechnology company that develops novel prodrugs of treprostinil for the treatment of pulmonary arterial hypertension using a once-daily transdermal patch.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Medical Devices
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Corsair Pharma Comparables
Compare Corsair Pharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| United Therapeutics | 74% | |
| Insmed Incorporated | 69% | |
| Gossamer Bio | 68% |
For institutional investors. Book with your work email.
Corsair Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 20, 2023 | ||||
| Strategic | Jan 3, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Corsair Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Midas Capital Management | Series B |
| Junson Capital | Series B |
| New Rhein Healthcare Investors | Series B |
| Plaisance Capital Management | Series B |
| Primavera Capital Group | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 15, 2025
New data on Treprostinil Prodrug Transdermal System to be presented at PHPN 2025.
- Sep 15, 2025
Will present new data at the PHPN 2025 Symposium.
For institutional investors. Book with your work email.
Corsair Pharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Corsair Pharma's valuation, stock price, and market status.
Is Corsair Pharma a public or private company?
Corsair Pharma is a private company.
What is the current stock price of Corsair Pharma?
Corsair Pharma is a private company, so its shares have no public market price. Caplight tracks Corsair Pharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Corsair Pharma worth (valuation)?
Valuation information for Corsair Pharma is not publicly available.
Can I buy Corsair Pharma stock?
Corsair Pharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Corsair Pharma's last funding round?
Corsair Pharma's most recent funding round was Series B on September 20, 2023.
Who are the main investors in Corsair Pharma?
Key investors in Corsair Pharma include New Rhein Healthcare Investors.
Will Corsair Pharma IPO soon?
No public IPO plans have been announced for Corsair Pharma.
How can I track Corsair Pharma secondary market activity?
Caplight tracks bids, offers, and trades in Corsair Pharma's shares on secondary markets.